Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

rad data australia pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; purified talc; magnesium stearate - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; magnesium stearate; sodium starch glycollate; microcrystalline cellulose; lactose monohydrate; macrogol 400 - zolpidem sandoz is indicated for the short-term treatment of insomnia in adults.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - zolpidem tartrate, quantity: 12.5 mg - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hypromellose; sodium starch glycollate type a; magnesium stearate; macrogol 3350; potassium hydrogen tartrate; colloidal anhydrous silica; titanium dioxide; iron oxide yellow; indigo carmine - stilnox cr is indicated for the short term treatment of insomnia in adults.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - zolpidem tartrate, quantity: 6.25 mg - tablet, modified release - excipient ingredients: lactose monohydrate; microcrystalline cellulose; hypromellose; sodium starch glycollate type a; magnesium stearate; macrogol 3350; potassium hydrogen tartrate; colloidal anhydrous silica; titanium dioxide; iron oxide red - stilnox cr is indicated for the short term treatment of insomnia in adults.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; titanium dioxide; hypromellose; polysorbate 80; macrogol 400 - short-term treatment of insomnia in adults.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; hypromellose; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 400 - short-term treatment of insomnia in adults.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - zolpidem tartrate, quantity: 10 mg - tablet, film coated - excipient ingredients: macrogol 400; hypromellose; lactose monohydrate; magnesium stearate; microcrystalline cellulose; titanium dioxide; sodium starch glycollate - dormizol is indicated for the short term treatment of insomnia in adults.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - zopiclone, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose; calcium hydrogen phosphate; magnesium stearate; maize starch; povidone; titanium dioxide; hypromellose; macrogol 400 - short-term treatment of insomnia (7 - 14 days).

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - zopiclone, quantity: 7.5 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; purified talc; povidone; maize starch; sodium starch glycollate type a; hypromellose; lactose monohydrate; titanium dioxide; calcium hydrogen phosphate dihydrate; macrogol 6000 - short term treatment of insomnia (7 to 14 days)

Израел - Енглески - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.